Metabolomic Analysis Reveals Extended Metabolic Consequences of Marginal Vitamin B-6 Deficiency in Healthy Human Subjects

Jesse F. Gregory III⁵*, Youngja Park⁶ᵇ, Yvonne Lamers¹ᵃ, Nirmalya Bandyopadhyay³, Yueh-Yun Chi⁴, Kichen Lee², Steven Kim², Vanessa da Silva¹, Nikolas Hove⁵, Sanjay Ranka³, Tamer Kahveci³, Keith E. Muller⁶, Robert D. Stevens⁷, Christopher B. Newgard⁷, Peter W. Stacpoole⁸,⁹, Dean P. Jones²

¹ Food Science and Human Nutrition Department, Institute of Food and Agricultural Sciences, University of Florida, Gainesville, Florida, United States of America, ² Clinical Biomarkers Laboratory, Division of Pulmonary, Allergy and Critical Care Medicine, Department of Medicine and Center for Clinical and Molecular Nutrition, Department of Medicine, Emory University, Atlanta, Georgia, United States of America, ³ Computer and Information Science and Engineering, University of Florida, Gainesville, Florida, United States of America, ⁴ Department of Biostatistics, University of Florida, Gainesville, Florida, United States of America, ⁵ Industrial Engineering Department, Hanyang University, Seoul, Korea, ⁶ Department of Health Outcomes and Policy, University of Florida, Gainesville, Florida, United States of America, ⁷ Sarah W. Stedman Nutrition and Metabolism Center, Duke University Medical Center, Durham, North Carolina, United States of America, ⁸ Division of Endocrinology and Metabolism, Department of Medicine, University of Florida, Gainesville, Florida, United States of America, ⁹ Department of Biochemistry and Molecular Biology, College of Medicine, University of Florida, Gainesville, Florida, United States of America

Abstract

Marginal deficiency of vitamin B-6 is common among segments of the population worldwide. Because pyridoxal 5'-phosphate (PLP) serves as a coenzyme in the metabolism of amino acids, carbohydrates, organic acids, and neurotransmitters, as well as in aspects of one-carbon metabolism, vitamin B-6 deficiency could have many effects. Healthy men and women (age: 20-40 y; n = 23) were fed a 2-day controlled, nutritionally adequate diet followed by a 28-day low-vitamin B-6 diet (<0.5 mg/d) to induce marginal deficiency, as reflected by a decline of plasma PLP from 52.6±14.1 (mean ± SD) to 21.5±4.6 nmol/L (P<0.0001) and increased cystathionine from 131±0.5 mg/dL to 199±56 mg/dL (P<0.001). Fasting plasma samples obtained before and after vitamin B6 restriction were analyzed by ¹H-NMR with and without filtration and by targeted quantitative analysis by mass spectrometry (MS). Multilevel partial least squares-discriminant analysis and S-plots of NMR spectra showed that NMR is effective in classifying samples according to vitamin B-6 status and identified discriminating features. NMR spectral features of selected metabolites indicated that vitamin B-6 restriction significantly increased the ratios of glutamine/glutamate and 2-oxoglutarate/glutamate (P<0.001) and tended to increase concentrations of acetate, pyruvate, and trimethylamine-N-oxide (adjusted P<0.05). Tandem MS showed significantly greater plasma proline after vitamin B-6 restriction (adjusted P<0.05), but there were no effects on the profile of 14 other amino acids and 45 acylcarnitines. These findings demonstrate that marginal vitamin B-6 deficiency has widespread metabolic perturbations and illustrate the utility of metabolomics in evaluating complex effects of altered vitamin B-6 intake.

Introduction

Vitamin B-6 exists in many dietary sources, yet an individual’s particular food consumption pattern and certain drug-nutrient interactions can lead to low vitamin B6 status. The vitamin B-6 status of much of the United States population is adequate. However, the lower percentiles of intake are associated with low vitamin B-6 status [1,2] that is more prevalent in smokers, women and the elderly [1,3,4]. Many inflammatory conditions also are associated with lower vitamin B-6 status regardless of intake [5,6], but the mechanism is unknown. The use of certain common drugs such as theophylline [7] and oral contraceptive agents [1,8] also is associated with reduced vitamin B-6 status.

The coenzymic form of vitamin B-6, pyridoxal phosphate (PLP), serves as a coenzyme for over 140 enzymes in human metabolism. PLP is thus involved in a wide array of functions [9] including: the catabolism and interconversion of most amino acids; the formation
of various organic acids, including species involved in the TCA cycle and gluconeogenesis; heme synthesis; and several key steps in pathways associated with one-carbon metabolism. Vitamin B-6 deficiency also is associated with interconversions of long-chain polyunsaturated fatty acids.

Plasma PLP concentration of 20 nmol/L reflects vitamin B-6 deficiency [3], while 20–30 nmol/L indicates marginal status [10,11]. The consequences of marginal deficiency are unclear, but chronically low vitamin B6 status is associated with increased risk of cardiovascular disease [12–17], deep-vein thrombosis [18–20], stroke [21] and certain cancers [22,23]. The mechanisms responsible for these disease connections are unknown but do not appear to be associated with hyperhomocysteinemia [5]. In view of the many coenzymic roles of PLP, further investigation of the in vivo metabolic consequences of inadequate vitamin B6 status may provide better insight into the effects of marginal vitamin B-6 deficiency.

We have investigated the consequences of inadequate vitamin B6 status using a series of protocols that involve the use of controlled low-vitamin B-6 diets in healthy volunteers [24–29]. In these studies, we employed targeted metabolite profiling and in vivo stable isotope tracer kinetic protocols to derive functional information about specific vitamin-dependent processes in one-carbon metabolism and related pathways while the participants were in adequate and marginal vitamin B6 status. These studies led to the following major observations concerning the effects of vitamin B-6 restriction: (a) surprising resiliency of one-carbon metabolism to effects of vitamin B6 deficiency, (b) changes glycine kinetics and concentration, (c) the resiliency of transsulfuration flux concurrent with an expansion of the cystathionine pool, (d) individual variability in the kinetics of glutathione synthesis, and (e) altered patterns of circulating n-3 and n-6 polyunsaturated fatty acids [24–29]. This work has led to new insights into PLP-dependent metabolic processes and the influence of vitamin B6 nutritional status.

Advances in both NMR and mass spectral aspects of metabolomics have impacted many facets of biology including the nutritional sciences [30,31]. The nutritional applications of NMR metabolomics to date have tended to focus on dietary effects on macronutrient metabolism and intermediary metabolites (for example, [32,33], with few applications of these powerful tools in characterizing the metabolic effects varying levels of micronutrient status (for example, [34]). The direct analysis of plasma or urine by NMR provides a useful approach that complements mass spectrometry for evaluating metabolic phenotypes associated with nutritional adequacy and deficiency and for evaluating nutrient-gene and nutrient-disease interactions.

The study reported here was conducted to investigate the impact of controlled vitamin B-6 depletion through the use of 1H-NMR analysis of plasma from 23 healthy participants from two recent vitamin B-6 restriction studies [27,28]. We examined NMR spectra of intact plasma with and without deproteination by filtration as an untargeted means of evaluating vitamin B6-dependent changes in plasma constituents. The results were evaluated using multivariate analysis accounting for the paired structure of the data to assess differences in spectral patterns and metabolite profiles. On a subset of these samples (n = 18) we also performed provisional quantification on selected metabolites by spectral curve fitting (Chenomx). Because of the critical role of vitamin B6 in the metabolism of amino acids and organic acids, we also conducted targeted metabolite profile analysis of amino acids, selected organic acids and acylcarnitines using quantitative analyses of NMR signals, and mass spectrometry.

**Materials and Methods**

Participants and nutritional protocols

The blood samples for this study were obtained as described previously [27,28] from healthy men (n = 12) and women (n = 11), aged 20–40 y, who participated in two identical dietary vitamin B6 restriction protocols designed to assess the metabolic effects of marginal vitamin B6 status. Health was determined by physical examination and routine tests of hepatic, renal, thyroid and hematological function [27,28]. No participant had a history of...
gastrointestinal surgery, chronic disease, smoking or chronic drug use or alcoholism, body mass index not greater than 28 kg/m², vitamin, amino acid, or protein supplementation, or chronic consumption of a high-protein diet. Nutritional adequacy was indicated normal concentrations of serum folate (greater than 7 nmol/L), serum vitamin B-12 (greater than 200 pmol/L), plasma PLP (greater than 30 nmol/L), and plasma total homocysteine (less than 12 μmol/L). All participants gave written informed consent. The study was approved by the University of Florida Institutional Review Board and the UF Clinical Research Center (CRC) Scientific Advisory Committee. This study was registered at clinicaltrials.gov as NCT00877812.

The experimental protocol consisted of two dietary periods with a metabolic assessment of tracer kinetics and blood sampling for metabolite profiling at the end of each [27,28]. The first consisted of a 2-d nutritionally adequate controlled diet (total vitamin B-6 = 1.02±0.11 mg/d), followed by the first metabolic assessment of participants in documented adequate vitamin B6 status. The second period involved a 28-d low vitamin B-6 diet to induce a state of marginal vitamin B-6 deficiency (PLP ~20 nmol/L), followed immediately by a metabolic assessment identical to the first. The vitamin B-6 restriction diet (total vitamin B-6 = 0.37±0.04 mg/d) provided total protein intake of 1 g kg⁻¹ d⁻¹ and mean methionine and cystine intake of 21 and 17 mg kg⁻¹ d⁻¹, respectively. During both metabolic assessments, blood samples analyzed in this metabolomic analysis were obtained in the morning after withholding food overnight and were followed by primed, constant infusion protocols reported previously [27,28]. The analyses reported here were performed on plasma obtained before and after the 28-d vitamin B-6 restriction period. The samples taken for NMR and mass spectral analysis were drawn by syringe from an indwelling catheter in an antecubital vein, mixed gently in a sodium EDTA tube, cooled on ice, centrifuged within 15 min of collection and then stored at −80°C.

Figure 2. S-plots from multilevel PLS-DA show that ¹H-NMR signals from many metabolites contribute to separation of vitamin B6 adequate and vitamin B6 restricted conditions. Panels A and B: S-plots that respectively correspond with the score plots in Figure 1A (Not Filtered) and Figure 1B (Filtered) plasma. In these panels, the top 5% of metabolites that contribute to 95% of the separation of baseline and restricted samples are highlighted in red squares. Red-framed points within the ovals represent the most highly discriminating signals. Panels C and D: loading plots illustrating discriminating spectral features from S-plots. Covariance of each discriminating feature is superimposed on the corresponding NMR chemical shift on mean spectra.

doi:10.1371/journal.pone.0063544.g002
**Targeted quantitative analysis**

Measurement of plasma PLP [25,35] and aminothiols (total glutathione, cysteine, and homocysteine; [36]) was performed by fluorometric HPLC. Plasma cystathionine, a sensitive functional biomarker of vitamin B-6 deficiency [26,27,37], was determined by gas chromatography-mass spectrometry [38]. Plasma concentrations of free amino acids and acylcarnitines were determined by electrospray tandem mass spectrometry using isotope dilution techniques [39]. We determined plasma glucose concentration using a commercial hexokinase-based assay kit (Sigma GAHK-20).

**NMR analysis**

**1H-NMR spectroscopy.** 1H-NMR spectra were obtained at 600 MHz on a Varian INOVA 600 spectrometer with water presaturation at 25°C as described above. As described for previous 1H-NMR studies of human plasma conducted by the Emory Clinical Biomarkers Laboratory [32], the identity of major signals was supported by the addition of standards (amino acids, organic acids, energy intermediates), comparisons to spectra in chemical databases, reference to a rigorous description of NMR spectra of human plasma [43], application of the Chenomx database, and confirmation with 2-dimensional (2-D) NMR techniques.

**Quantitative 1H-NMR analysis of metabolites.** The analysis of NMR spectra from filtered samples utilizing spectral fitting techniques (Chenomx, Edmonton, Alberta, Canada) allowed estimation of the concentrations of major plasma constituent small molecules [45,46]. For 5 of the 23 participants, at least one of the NMR spectra did not meet the criteria needed for the Chenomx analysis. Therefore, the identity of major signals was supported by the addition of standards (amino acids, organic acids, energy intermediates), comparisons to spectra in chemical databases, reference to a rigorous description of NMR spectra of human plasma [43], application of the Chenomx database, and confirmation with 2-dimensional (2-D) NMR techniques.

**Table 1.** Estimated concentration of selected plasma constituents before and after vitamin B-6 restriction determined in filtered plasma by Chenomx spectral fitting analysis of 1H-NMR.

| Variable                        | Baseline | Vitamin B-6 Restricted | Adjusted P ¹                   |
|--------------------------------|----------|------------------------|--------------------------------|
|                                | mmol/L   | mmol/L                 |                                |
| Acetate                        | 56±23    | 79±49                 | 0.028                          |
| Acetoacetate                   | 49±38    | 42±28                 | 0.493                          |
| Acetone                        | 36±22    | 39±27                 | 0.317                          |
| Asparagine                     | 50±23    | 75±33                 | 0.011                          |
| Aspartate                      | 49±27    | 63±30                 | 0.055                          |
| Choline                        | 36±33    | 37±24                 | 0.448                          |
| Formate                        | 61±18    | 79±48                 | 0.158                          |
| Glutamate                      | 78±37    | 61±26                 | 0.011                          |
| Glutamine                      | 130±150  | 205±201               | <0.001                         |
| Myo-Inositol                   | 23±12    | 39±21                 | 0.011                          |
| 2-Oxoglutarate                 | 37±14    | 51±21                 | <0.001                         |
| Pyruvate                       | 94±54    | 121±61                | 0.028                          |
| Succinate                      | 26±13    | 30±16                 | 0.305                          |
| Trimethylamine-N-oxide         | 9±10     | 17±16                 | 0.004                          |
| Urea                           | 1250±180 | 1130 ± 884            | 0.493                          |

1Mean ± SD, n = 18. Concentrations approximated from the respective singlet resonances using Chenomx spectral fitting analysis.

2Adjusted P-value through controlling positive FDR after paired t-tests on changes on log2 transformed concentrations. * designates significant difference at P<0.05. The effect of vitamin B-6 restriction on the overall pattern of constituents in Chenomx analysis was significant in multivariate testing, P = 5.3 x 10⁻⁷. doi:10.1371/journal.pone.0063544.t001

**Table 2.** Ratios of selected plasma constituents determined in filtered plasma by 1H-NMR, before and after vitamin B-6 restriction.

| Variable                        | Baseline | Vitamin B-6 Restricted | P     |
|--------------------------------|----------|------------------------|-------|
| Transamination ratios          |          |                        |       |
| Pyruvate/Alanine               | 0.280±0.093 | 0.296±0.095            | 0.554 |
| 2-Oxoglutarate/ Glutamate      | 0.556±0.303 | 0.984±0.582*            | 0.001 |
| Amidation ratios               |          |                        |       |
| Asparagine/Aspartate           | 1.20±0.56 | 1.39±0.66               | 0.250 |
| Glutamine/Glutamate            | 1.42±1.23 | 3.17±2.76*              | 0.001 |

¹Mean ± SD, n = 18.

²P value determined by paired t-test after log transformation. * designates a significant difference at P<0.05.

doi:10.1371/journal.pone.0063544.t002

Targeted quantitative analysis

Measurement of plasma PLP [25,35] and aminothiols (total glutathione, cysteine, and homocysteine; [36]) was performed by fluorometric HPLC. Plasma cystathionine, a sensitive functional biomarker of vitamin B-6 deficiency [26,27,37], was determined by gas chromatography-mass spectrometry [38]. Plasma concentrations of free amino acids and acylcarnitines were determined by electrospray tandem mass spectrometry using isotope dilution methods [39]. We determined plasma glucose concentration using a commercial hexokinase-based assay kit (Sigma GAHK-20).

**NMR analysis**

**1H-NMR spectroscopy.** 1H-NMR spectra were obtained at 600 MHz on a Varian INOVA 600 spectrometer with water presaturation at 25°C as described above. As described for previous 1H-NMR studies of human plasma conducted by the Emory Clinical Biomarkers Laboratory [32], the identity of major signals was supported by the addition of standards (amino acids, organic acids, energy intermediates), comparisons to spectra in chemical databases, reference to a rigorous description of NMR spectra of human plasma [43], application of the Chenomx database, and confirmation with 2-dimensional (2-D) NMR techniques.

**Quantitative 1H-NMR analysis of metabolites.** The analysis of NMR spectra from filtered samples utilizing spectral fitting techniques (Chenomx, Edmonton, Alberta, Canada) allowed estimation of the concentrations of major plasma constituent small molecules [45,46]. For 5 of the 23 participants, at least one of the NMR spectra did not meet the criteria needed for the Chenomx analysis. Therefore, quantitative analysis is reported only on the 18 participants for which pre- and post-vitamin B-6 restriction data were obtained. We report from this analysis estimates of the concentrations of 15 plasma constituents for these 18 participants before and after vitamin B-6 restriction.

**Data analysis**

Principal Component Analysis (PCA) and Orthogonal Signal Correction-Partial Least Squares Discriminant Analysis (OPLS-DA) of processed spectra were performed using Pirouette software.
Metabolomic Analysis of Vitamin B-6 Deficiency

Table 3. Concentration of plasma free amino acids and glutathione determined by targeted quantitative methods before and after vitamin B-6 restriction.1

| Variable            | Method      | Baseline μmol/L | Vitamin B-6 Restricted μmol/L | Adjusted P 2 |
|---------------------|-------------|-----------------|------------------------------|--------------|
| Alanine             | Tandem MS   | 377±112         | 396±77                       | 0.281        |
| Arginine            | Tandem MS   | 94±26           | 86±17                        | 0.281        |
| Asx                 | Tandem MS   | 77±21           | 74±16                        | 0.577        |
| Citrulline          | Tandem MS   | 33±10           | 34±9                         | 0.577        |
| Cystathionine       | GC-MS       | 131±65          | 199±56*                      | <0.001       |
| Cysteine (total)    | HPLC        | 256±39          | 253±36                       | 0.577        |
| Gln                 | Tandem MS   | 73±24           | 82±32                        | 0.281        |
| Glutathione (total) | HPLC        | 7.17±1.84       | 7.15±1.26                    | 0.855        |
| Glycine             | Tandem MS   | 357±83          | 393±95                       | 0.281        |
| Histidine           | Tandem MS   | 82±13           | 77±18                        | 0.281        |
| Homocysteine (total)| HPLC        | 6.97±1.26       | 6.97±1.33                    | 0.925        |
| Leucine/Isoleucine  | Tandem MS   | 158±31          | 154±27                       | 0.577        |
| Methionine          | Tandem MS   | 25±6            | 26±6                         | 0.724        |
| Ornithine           | Tandem MS   | 47±11           | 49±12                        | 0.483        |
| Phenyllalanine      | Tandem MS   | 78±21           | 74±19                        | 0.281        |
| Proline             | Tandem MS   | 190±90          | 223±84*                      | 0.004        |
| Serine              | Tandem MS   | 115±24          | 125±33                       | 0.281        |
| Tyrosine            | Tandem MS   | 75±17           | 71±13                        | 0.329        |
| Valine              | Tandem MS   | 196±34          | 190±29                       | 0.565        |

1Mean ± SD, n = 23.
2Adjusted P-value through controlling positive FDR after paired t-tests on changes on log2 transformed concentrations. * designates significant difference at P<0.05.

The effect of vitamin B-6 restriction on the overall pattern of constituents was significant in multivariate testing, P = 0.0296.
doi:10.1371/journal.pone.0063544.003

(Infometrix, Bothell, WA). PCA and OPLS-DA score plots and loading plots of NMR spectral data were used to visualize relational patterns and discriminatory factors to classify the groups. The OPLS-DA procedure, being a supervised technique (i.e., treatment groupings included in the analysis), removes variation not correlated to classification after centering the mean value for each frequency [33,40,47]. Data were evaluated for unfiltered and filtered plasma using score plots in OPLS-DA analysis to evaluate the classification according to vitamin B-6 status. For each discriminating spectral region, we assigned the analysis to evaluate the classification according to vitamin B-6 unfiltered and filtered plasma using score plots in OPLS-DA value for each frequency [33,40,47]. Data were evaluated for variation not correlated to classification after centering the mean (i.e., treatment groupings included in the analysis), removes groups. The OPLS-DA procedure, being a supervised technique relational patterns and discriminatory factors to classify the loading plots of NMR spectral data were used to visualize run on the paired data structure. Additonal analysis to identify and adjusted to generate paired data structure. Lastly OPLS-DA was conducted multilevel PLS-DA as described by Westerhuis et al. [38] as follows. First, the paired structure was created by averaging of amide versus acid forms of glutamate and aspartate. The log base 2 transformation using a recently developed method for global hypothesis testing in repeated measures high-dimensional data [49]. The log base 2 transformation was a means to meet the Gaussian requirement. For subsequent local hypothesis testing, we evaluated differences in the transformed concentration of individual plasma constituents using paired t-test and the positive false discovery rate method [50] to adjust p-values in anticipation of the inflation of false positive rate as a result of multiple testing. The effects of change in plasma PLP and change in plasma cystathionine were evaluated using the test for Pearson correlation coefficient in conjunction with the positive false discovery rate method to account for multiple testing.

Ratios of selected metabolites derived from NMR analysis were evaluated to assess product/precursor relationships before and after vitamin B-6 restriction. Asparagine/aspartic acid and pyruvate/alanine ratios served as static indicators of the proportions of amide versus acid forms of glutamate and aspartate. The ratios of pyruvate/alanine and 2-oxoglutarate/glutamate provided a measure of the product/precursor ratio for these aminotransferases.

Plots of covariance versus correlation for spectral data [48] followed by loading plots of covariance versus chemical shift on mean spectra. After calculation of the top 5% of discriminatory loadings in this analysis (647 and 381 for unfiltered and filtered plasma, respectively), we visually selected points (65 and 26 for unfiltered and filtered, respectively) in regions of the S-plots that were clearly separated from the central risk zone. These represented the most highly discriminating features.

Further statistical analysis of metabolite concentrations was performed after log base 2 transformation using a recently developed method for global hypothesis testing in repeated measures high-dimensional data [49]. The log base 2 transformation was a means to meet the Gaussian requirement. For subsequent local hypothesis testing, we evaluated differences in the transformed concentration of individual plasma constituents using paired t-test and the positive false discovery rate method [50] to adjust p-values in anticipation of the inflation of false positive rate as a result of multiple testing. The effects of change in plasma PLP and change in plasma cystathionine were evaluated using the test for Pearson correlation coefficient in conjunction with the positive false discovery rate method to account for multiple testing.

Ratios of selected metabolites derived from NMR analysis were evaluated to assess product/precursor relationships before and after vitamin B-6 restriction. Asparagine/aspartic acid and pyruvate/alanine ratios served as static indicators of the proportions of amide versus acid forms of glutamate and aspartate. The ratios of pyruvate/alanine and 2-oxoglutarate/glutamate provided a measure of the product/precursor ratio for these aminotransferases.
A level of statistical significance of 0.05 was employed in all procedures.

Results

Efficacy of the vitamin B-6 restriction protocol

The dietary protocol provided a controlled, nutritionally adequate 2-day stabilization period followed by very low vitamin B-6 intake for 28 days, and this protocol is effective for selectively inducing a state of marginal vitamin B-6 deficiency in healthy adults [25,51,52]. Plasma PLP concentration declined from 52.6±14.1 (mean ± SD) to 21.5±4.6 nmol/L (P<0.0001), which indicated a change from adequate vitamin B-6 status to marginal deficiency. Additional descriptive data regarding the 23 participants in this protocol have been reported in part previously [27–29] and are summarized (Table S1).

Metabolic effects of vitamin B-6 restriction

Global statistical analysis of 1H NMR spectral data. 1H-NMR analysis of plasma samples yielded spectra that were qualitatively similar to those originally reported and annotated by Nicholson and colleagues [43,53]. Filtration of plasma attenuated the regions of the spectrum attributable to lipids and proteins, as expected. Representative spectra of unfiltered and filtered plasma in vitamin B-6 adequate and restricted states are presented in Figure S1.

Statistical analysis of spectra first involved assessing the change in overall spectral data (before versus after vitamin B-6 restriction) using a recent method for global hypothesis testing for high-dimensional repeated measures outcomes of pairwise data [49]. By this method, the overall change across the entire spectrum was not significant for unfiltered plasma (p-value = 0.432) and filtered plasma (p-value = 0.549). Gender also had no significant effect on the overall change for unfiltered plasma (p-value = 0.683) or filtered plasma (p-value = 0.275) in this analysis. Because this n = 23 data set was derived from two equivalent vitamin B-6 restriction trials, we also tested for effects of trial 1 versus trial 2. The effect of trial (1 versus 2) had no significant effect on the overall change for unfiltered plasma (p-value = 0.103) or filtered plasma (p-value = 0.346).

Multilevel PLS-DA evaluation of 1H-NMR spectra to assess effects of vitamin B-6 restriction in paired data. Principal Component Analysis that did not account for paired structure of the spectral data obtained before and after vitamin B-6 restriction showed no separation or grouping of data according to vitamin B-6 status for both unfiltered and filtered plasma (data not shown). OPLS-DA, which is a supervised technique in which treatment groupings are identified, yielded unambiguous classification of data patterns according to nutritional status (i.e., pre- and post-vitamin B-6 restriction) for both unfiltered and filtered plasma (not shown). This provided evidence of extended compositional differences associated with vitamin B-6 restriction, although the OPLS-DA method also did not account for the paired data structure.

Multilevel PLS-DA [54], which is an approach to multivariate analysis that incorporates provisions for paired data, showed distinct separation according to vitamin B-6 status in both unfiltered and filtered plasma (Figure 1). For unfiltered plasma, the first orthogonal component (40% of total variation) and the first principal component explained 40% and 30% of the total variation, respectively. For filtered plasma the first orthogonal component and the first principal component explained 29% and 60% of total variation, respectively. S-plots derived from this analysis of 1H-NMR data in the multilevel PLS-DA allowed detection of the spectral regions that discriminated between vitamin B-6 adequacy (baseline) and restricted conditions for both filtered and unfiltered plasma (Figure 2A and 2B). When discriminating features were superimposed on mean spectra (Figure 2C and 2D), the discriminating regions appeared to be primarily attributable to lipids, organic acids and amino acids for unfiltered plasma and organic acids, and amino acids for filtered plasma (Figure 2C and 2D).

Vitamin B-6 restriction affects the plasma metabolite profile. Analysis using NMR spectral fitting provided an estimation of the concentration of selected plasma constituents for which methods of targeted quantitative analysis were not readily available in this study. We report here this analysis using Chenomx software for acetate, acetoacetate, aspartate, asparagine, choline, formate, fumarate, glutamate, glutamine, lactate, myo-inositol, 2-oxoglutarate, pyruvate, succinate taurine and trimethylamine oxide in a subset (n = 18) of the participants (Table 1). Local hypothesis testing of changes in the estimated plasma concentrations derived from spectral features attributed to acetate, asparagine, glutamine, myo-inositol, lactate, 2-oxoglutarate, pyruvate, taurine and trimethylamine-N-oxide significantly increased (adjusted P<0.05), while that of glutamate significantly decreased (adjusted P<0.05) (Table 1).

The evaluation of the ratios of several of these plasma constituents allowed us to probe possible biochemical effects of vitamin B-6 restriction. Whereas spectral features attributable to asparagine and glutamine concentrations increased (Table 1), the ratios reflecting the relative extent of amidation differed (Table 2). Vitamin B-6 restriction did not significantly change the asparagine/aspartate ratio, but the ratio of glutamine/glutamate more than doubled due to the restriction (P<0.001). In addition, the ratio of the 2-ketoacids pyruvate and 2-oxoglutarate and the corresponding amino acids alanine and glutamate reflected the balance of respective aminotransferase reactions. The pyruvate/alanine ratio did not change significantly, while the 2-ketoglu-tarate/glutamate ratio increased 76% due to vitamin B-6 restriction (P<0.001). The ratio of plasma lactate/pyruvate, which is indicative of cytoplasmic redox state and cellular respiration, did not change due to vitamin B-6 restriction (8.3±2.0 versus 7.6±1.5; P = 0.242).

The concentration of amino acids and glutathione determined by targeted quantitative methods (tandem mass spectrometry, GC-MS and HPLC) revealed significant effects of vitamin B-6 restriction (Table 3). Plasma cystathionine, which is a functional biomarker of vitamin B-6 deficiency indicating functional impairment of the transsulfuration pathway [27,37,38], increased markedly (adjusted P = 0.0002). Plasma proline exhibited an unexpected increase (adjusted P<0.05), but there was no significant change in most of the other amino acids evaluated (alanine, arginine, asx, citrulline, gb, glycine, histidine, leucine + isoleucine, methionine, ornithine, phenylalanine, serine, tyrosine, and valine). In this context, asx and gb refer to the concentrations of aspartate and glutamate plus a contribution from partial hydrolysis of their amides, asparagine and glutamine, under the conditions of the tandem mass spectral analysis. The concentration of plasma glucose measured enzymatically was not changed by vitamin B-6 restriction (4.71±0.676 versus 4.52±0.543 mmol/L; adjusted P = 0.122). We found no change in the concentrations of 45 acylcarnitines or in total acylcarnitines (adjusted P = 0.747).
Discussion

Effectiveness of the vitamin B-6 restriction protocol

The controlled vitamin B-6 restriction protocol employed in this study provided a novel and reproducible tool for investigating metabolic effects of marginally deficient vitamin B-6 status [24–28]. We recognize, however, that the short term metabolic effects of marginal vitamin B-6 status may not reflect the mechanisms responsible for the association of chronic low vitamin B-6 status with greater long-term risk of various forms of chronic disease. We also recognize that subtle differences between the controlled diet and the previous self-selected diet of the participants could contribute to observed metabolite patterns. This protocol constituted an opportunity in which to investigate the utility of metabolomic approaches in the context of controlled low vitamin B-6 status over a relatively brief period. To our knowledge, this is the first report of the use of combined global and targeted metabolomic approaches for probing micronutrient deficiency of any type.

Metabolomic tools in vitamin B-6 research

The combined NMR and targeted mass spectral analysis in this study yielded new insights into the metabolic effects of vitamin B-6 restriction. They also indicate the merits of concurrently using NMR and mass spectrometry in nutritional metabolomics. 1H-NMR has several analytical strengths when investigating micronutrient status. First, NMR can detect differences in overall plasma composition in both whole (unfiltered) plasma and following filtration to remove most proteins, lipids and lipoproteins. Minimal sample preparation is required, and aspects of the procedure are suitable for automation. Second, because of the comparatively low sensitivity of 1H-NMR (relative to mass spectrometry-based procedures), the spectra reflect the metabolic phenotype at the level of macronutrients and their metabolites. This provides a particularly useful tool in evaluating the widespread effects of its micronutrient restriction on human metabolism. The focus of 1H-NMR on relatively high-concentration plasma constituents, such as amino acids and organic acids, yields a broad assessment of the direct and indirect effects of vitamin B-6 restriction on human intermediary metabolism. Third, our results show that 1H-NMR has potential as a diagnostic technique that compliments conventional analysis of a single biomarker (e.g., plasma PLP) in characterizing marginal vitamin B-6 deficiency. Further investigation will be needed to validate this diagnostic application more fully.

Based on the current data, the sensitivity and specificity of multilevel PLS-DA of NMR spectra in reflecting overall metabolic effects of vitamin B-6 restriction are excellent. The minimal sample preparation needed for NMR analysis preserves the patterns of labile compounds such as asparagine and glutamine. However, the estimation of metabolite concentrations by spectral fitting using techniques such as illustrated here with Chenomx software should not be viewed as quantitatively conclusive. Confirmatory targeted analysis should be conducted wherever possible, especially for these metabolites in which changes are subtle. In the case of free amino acids such as asparagine, aspartate, glutamate and glutamine, differences between NMR-based and targeted mass spectrometry-based analyses may partially be attributable to NMR response to amino acid residues in the plasma peptides [55] that would be present in the ultrafiltrates used in NMR-Chenomx analysis. Other sources of variability in metabolite quantification by spectral fitting have been reported [56].

Metabolic consequences of vitamin B-6 restriction

Because pyridoxal phosphate serves a coenzymatic function in over 140 reactions, the potential for metabolic effects of vitamin B-6 deficiency extends broadly through many phases of human metabolism. As illustrated by our previous studies involving the transsulfuration enzymes cystathionine β-synthase and cystathionine γ-lyase [26,28], PLP binding affinity is not fully informative of impairment caused by vitamin B-6 restriction. Broadly focused metabolite profiling methods allow one to assess more fully the extended effects of a nutritional condition, such as marginal vitamin B-6 deficiency.

Many reactions of the interconversion and catabolism of amino acids require PLP. PLP-dependent aspects of one-carbon metabolism (cytoplasmic and mitochondrial serine hydroxymethyltransferases and the mitochondrial glyoxylate cleavage system) that regulate these amino acids play an important role in the supply and balance of 1C units in metabolism [25,27]. Applications of in vivo stable isotopic tracer kinetics and mathematical modeling have shown situations in which in vivo fluxes of PLP-dependent processes and substrate/product concentrations are not totally predicted by vitamin B-6 status. For example, although the in vitro activities of cytoplasmic serine hydroxymethyltransferase (SHMT) and mitochondrial SHMT are strongly influenced by vitamin B-6 status [25,57], in vivo SHMT flux is relatively resilient to marginal deficiency [25,58]. Likewise, overall transsulfuration flux and cysteine production are maintained during marginal vitamin B-6 deficiency [26,28] despite the sensitivity of the cystathionine γ-lyase reaction to cellular PLP deficiency and resulting buildup of cystathionine in tissues and plasma [27,37,38]. The PLP-dependent mitochondrial glyoxylate cleavage system accounts for approximately 20 times more 5,10-methylenetetrahydrofolate production than needed for cellular methyl synthesis demands [59]. The increased glycine concentration frequently observed in marginal vitamin B-6 deficiency presumably reflects substrate accumulation due to reduced activity of the glyoxylate cleavage system [25,27,58]. However, in vivo tracer kinetic results indicate no significant reduction in glycine cleavage system flux from vitamin B-6 restriction [27].

The spectral features reflecting substantial increases in asparagine and glutamine and the marked increase in the glutamate/glutamine ratio (Table 2) observed here were unexpected. Neither glutamine synthetase, which catalyzes ATP-dependent condensation of glutamate and ammonia, nor asparagine synthetase, which catalyzes the ATP-dependent transfer of the terminal amidic group of glutamine to aspartate, requires PLP, nor do the catabolic enzymes glutaminase and asparaginase. In view of the importance of inter-organ transport of glutamine and the regulatory role of glutaminases [60,61], our findings suggest fundamental perturbations in the inter-organ trafficking of these amino acids may be responsible for the changes in their plasma concentrations associated with vitamin B-6 restriction. The unexpected increase in plasma proline suggests that it may be a secondary consequence of the altered glutamate and glutamine concentrations because proline synthesis occurs by way of pyrroline 5-carboxylate [60]. It is likely that the changes in plasma myo-inositol and trimethylamine oxide were mainly attributable to differences in diet composition from the participants’ pre-study diets, because their metabolism does not directly involve PLP-dependent processes.

The activity and extent of coenzyme saturation of PLP-dependent aminotransferases has long been recognized and used diagnostically in assessing vitamin B-6 status [62]. However, the impact of vitamin B-6 insufficiency on the profile of tissue and plasma amino acids and, particularly, the sensitivity of such reactions in maintaining anaplerotic reactions remains unclear.
Increases in plasma concentrations of pyruvate and 2-oxoglutarate may reflect reduced utilization of 2-ketoacids in aminotransferase reactions or in other phases of metabolism. The lack of a significant change in formate concentration is consistent with findings from an NMR study in rats, in which deficiency of vitamin B-12, but not B-6 deficiency, caused an increase in plasma and urinary formate [63]. Changes in the profile of tryptophan catabolic products in the kynurenine pathway are associated with vitamin B-6 deficiency [10,64,65]. Targeted analysis has revealed such changes in tryptophan metabolites in the present study (reported separately).

We have previously shown that vitamin B-6 deficiency is associated with markedly increased total glutathione concentration in rat liver in direct proportion to the severity of the deficiency [66] and in altered glutathione synthesis in a subset of vitamin B-6 restricted healthy humans [67]. These responses may be due to oxidative stress associated with vitamin B-6 deficiency [68–70] independent of substrate availability, a hypothesis that has been supported by mathematical modeling [59]. The role of such oxidative stress and its impact on the plasma metabolome during vitamin B-6 deficiency is presently unknown.

Conclusions

This study demonstrates that our vitamin B-6 restriction protocol induces fundamental changes in the plasma metabolite profile, strongly suggesting that marginal vitamin B-6 deficiency exerts far-reaching effects on human metabolism. These observations extend our understanding of the impact and interpretation of the marginal nutritional status and will aid in hypothesis development in the design of future research regarding the mechanistic relationship between low vitamin B-6 status and chronic disease.

Supporting Information

Figure S1 Representative 1H-NMR spectra of unfiltered and filtered plasma from a single participant shown before and after vitamin B-6 restriction, with signals from EDTA designated. Small arrows designate visually apparent differences in certain spectral features of these spectra. (TIF)

Table S1 Baseline characteristics of 23 healthy men and women participating in the study. (DOCX)

Table S2 Concentration of individual and total acylcarnitines in plasma determined by tandem mass spectrometry before and after vitamin B-6 restriction. (DOCX)

Acknowledgments

The excellent technical assistance of Maria Ralat is gratefully acknowledged.

Author Contributions

Conceived and designed the experiments: JFG YL PWS. Performed the experiments: YL VdS RDS CBN YP DPJ. Analyzed the data: YP KI SK NB SR TK YYC NH KEM. Wrote the paper: JFG. Clinical oversight: PWS.

References

1. Morris MS, Picciano MF, Jacques PF, Selhub J (2006) Plasma pyridoxal 5′-phosphate in the US population: the National Health and Nutrition Examination Survey, 2003-2004. Am J Clin Nutr 87: 1446–1454.
2. Fulgenzi VL, Seld, Keast DR, Bailey RL, Dwyer J (2011) Foods, fortificants, and supplements: Where do Americans get their nutrients? J Nutr 141: 1847–1854.
3. Institute of Medicine, Food and Nutrition Board (1998) Dietary Reference Intakes: Thiamin, Riboflavin, Niacin, Vitamin B6, Folate, Vitamin B12, Pantothenic Acid, Biotin, and Choline. Washington, DC: National Academy Press.
4. Centers for Disease Control and Prevention (2012) Second National Report on Biochemical Indicators of Diet and Nutrition in the U.S. Population 2012. Atlanta (GA): National Center for Environmental Health. 1–494 p.
5. Loto V, Choy SW, Friso S (2011) Vitamin B6: a challenging link between nutrition and inflammation in CVD. Br J Nutr 1: 1–13.
6. Morris MS, Sakakeeny L, Jacques PF, Picciano MF, Selhub J (2010) Vitamin B-6 intake is inversely related to, and the requirement is affected by, inflammation status. J Nutr 140: 103–110.
7. Ubbink JB, van der Merve A, Delport R, Allen RH, Stabler SP, et al. (1996) The effect of a subnormal vitamin B-6 status on homocysteine metabolism. J Clin Invest 98: 177–184.
8. Lussana F, Zighetti ML, Bucciarelli P, Cugno M, Cattaneo M (2003) Blood levels of homocysteine, folate, vitamin B6 and B12 in women using oral contraceptives compared to non-users. Thromb Res 112: 37–41.
9. da Silva VR, Russell KA, Gregory JF (2012) Vitamin B-6 intake and urinary formate: do dietary sources matter? Am J Clin Nutr 96: 1421–1427.
10. Leklem J (1998) Vitamin B6. In: Shils ME, Olson JA, Zdon MC, editors. Modern Nutrition in Health and Disease, Ninth Edition. Baltimore, MD: Williams & Wilkins. 1413–1421.
11. Mackey A, Davis S, Gregory J (2005) Vitamin B6. In: Shils M, editor. Modern Nutrition in Health and Disease, 9th Ed. Baltimore, MD: Wilkins and Wilkins. 452–461.
12. Rimington EB, Willet WC, Hu FB, Sampson L, Colditz GA, et al. (1996) Folate and vitamin B6 from diet and supplements in relation to risk of coronary heart disease among women. JAMA 279: 359–364.
13. Robinson K, Arheart K, Refsum H, Brattstrom L, Boers G, et al. (1998) Low plasma vitamin B-6 status and urinary formate. Am J Clin Nutr 67: 547–551.
14. Robinson K, Gupta A, Dennis V, Arheart K, Chaudhary D, et al. (1996) Hyperhomocysteinemia confers an increased risk of atherosclerosis in end-stage renal disease and is closely linked to plasma folate and pyridoxine concentrations. Circulation 94: 2743–2748.
15. Dalery K, Lassier-Cacan S, Selhub J, Davignon J, Latour Y, et al. (1995) Homocysteine and coronary artery disease in French Canadian subjects: relation with vitamin B12, B6, pyridoxal phosphate, and folate. Am J Cardiol 75: 1107–1110.
16. Verhoef P, Stampfer MJ, Buring JE, Gaziano JM, Allen RH, et al. (1996) Homocysteine metabolism and risk of myocardial infarction: relation with vitamins B6, B12, and folate. Am J Epidemiol 143: 845–859.
17. Miller JW, Green R, Mungas DM, Reed BR, Jagust WJ (2002) Homocysteine, vitamin B6, and vascular disease in AD patients. Neurology 58: 1471–1475.
18. Hron G, Lombardi R, Eichinger S, Lecchi A, Kyrdle PA, et al. (2007) Low vitamin B6 levels and the risk of recurrent venous thromboembolism. Haematologica 92: 1250–1255.
19. Cattaneo M, Lombardi R, Lecchi A, Bucciarelli P, Mannucci PM (2001) Low plasma levels of vitamin B6 are independently associated with a heightened risk of deep-vein thrombosis. Circulation 104: 2442–2446.
20. Vannuzzo D, Pilotta L, Lombardi R, Lazzera G, Carluccio M, et al. (2007) Both vitamin B6 and total homocysteine plasma levels predict long-term atherothrombotic events in healthy subjects. Eur Heart J 28: 484–491.
21. Kelly PJ, Shah VE, Kistler JP, Barron M, Lee H, et al. (2003) Low vitamin B6 but not homocysteine is associated with increased risk of stroke and transient ischemic attack in the era of folate acid grain fortification. Stroke 34: e51–e54.
22. Carson SC, Orsini N, Wolk A (2010) Vitamin B6 and risk of colorectal cancer: a meta-analysis of prospective studies. JAMA 303: 1077–1083.
23. Johannsson M, Reilto C, Ueland PM, Vollset SE, Muhutin O, et al. (2010) Serum vitamin B levels and risk of lung cancer. JAMA 303: 2377–2383.
24. Cusckley G, Stacpoole P, Williamson J, Baumgarter T, Gregory JF (2001) Deficiencies of folate and vitamin B6 exert distinct effects on homocysteine, serine, and methionine kinetics. J Am Physiol Endocrinol Metab 281: E1102–E1110.
25. Davis SR, Scheer JB, Quinlivan EP, Coats BS, Stacpoole PW, et al. (2005) Dietary vitamin B-6 restriction does not alter rates of homocysteine remethylation or synthesis in healthy young women and men. Am J Clin Nutr 81: 648–653.
26. Davis S, Quinlivan E, Stacpoole P, Gregory JF (2006) Plasma glutathione and cystathionine concentrations are elevated but cysteine flux is unchanged by dietary vitamin B-6 restriction in young men and women. J Nutr 136: 373–378.
27. Lamers Y, Williamson J, Ratat M, Quinlivan EP, Gilbert LR, et al. (2009) Moderate dietary vitamin B-6 restriction raises plasma glycine and cystathionine concentrations while minimally affecting the rates of glycine turnover and glycine catabolism in healthy men and women. J Nutr 139: 452–460.

28. Lamers Y, Coats B, Ratat M, Quinlivan EP, Stacpoole PW, et al. (2011) Moderate vitamin B-6 restriction does not alter postprandial methionine cycle rates of remethylation, transmethylation, and total transulfuration but increases the fractional synthesis rate of cystathionine in healthy young men and women. J Nutr 141: 835–842.

29. Zhao M, Lamers Y, Ratat MA, Coats BS, Chi YY, et al. (2012) Marginal vitamin B-6 deficiency decreases plasma (n-3) and (n-6) PUFA concentrations in healthy men and women. J Nutr 142: 1791–1797.

30. Gennar JB, Bauman DE, Burris DG, Falda MI, Foscai HC, et al. (2004) Metabolomics in the opening decade of the 21st century: building the roads to individualized health. J Nutr 134: 2729–2732.

31. Zeisel SH, Foscai HC, Bauman DE, Bier DM, Bauman DE, et al. (2010) The influence of dietary vitamin B6 and other nutrients on the plasma metabolome. J Nutr 140: 1613–1616.

32. Park Y, Le NA, Yu T, Strobel F, Getts-Miller N, et al. (2011) A sulfur amino acid-free meal increases plasma lipids in humans. J Nutr 141: 1424–1431.

33. Go H, Chen H, Pan Z, Jackson AU, Talaty N, et al. (2007) Monitoring diet effects via biosignals and their implications for metabolomics studies. Anal Chem 79: 89–97.

34. Duggan GE, Joan Miller B, Jirik FR, Vogel HJ (2011) Metabolic profiling of vitamin C deficiency in Guio—/— mice using proton NMR spectroscopy. J Nutr 141: 163–173.

35. Ubbink JB, Serfontein WJ, de Villiers LS (1985) Stability of pyridoxal-5-phosphate semicarbazone: applications in plasma vitamin B6 analysis and population surveys of vitamin B6 nutritional status. J Chromatogr 342: 277–284.

36. Pfeiffer CM, Hoff DL, Gunter EW (1999) Rapid and accurate HPLC assay for cystathionine in human plasma using stereospecific enzymatic cleavage and detection with a fluorescence detector. J Chromatogr 861: 37–45.

37. Park YK, Linksma H (1970) Effect of vitamin B6 depletion in adult man on the excretion of cystathionine and other methionine metabolites. J Nutr 100: 110–116.

38. Davis SR, Quinlivan EP, Stacpoole PW, Gregory JF et al. (2006) Plasma glutathione and cystathionine concentrations are elevated but cysteine flux is unchanged by dietary vitamin B-6 restriction in young men and women. J Nutr 136: 373–378.

39. Ferrara GT, Wang P, Neto EG, Stevens RD, Bain J, et al. (2006) Genetic networks of liver metabolism revealed by integration of metabolic and transcriptional profiling. PLoS Genet 4(7): e1000834.

40. Park Y, Kim SB, Wang B, Blanco RA, Le NA, et al. (2009) Individual variation in macronutrient regulation measured by proton magnetic resonance spectroscopy of human plasma. Am J Physiol Regul Integr Comp Physiol 297: R202–209.

41. Forthofer J, Schuppe-Kastinien L, Jacobsson SP (2003) Peak alignment of NMR signals by means of a genetic algorithm.

42. Lee GC, Woodruff DI (2006) Beam search for peak alignment of NMR signals. Analytica Chimica Acta 513: 413–416.

43. Nicholson JK, Nicholls DJ, Spraul M, Farrant RD, Lindon JC (1995) 750 MHz 1H nuclear magnetic resonance-based metabolic profiling: quantitative analysis of 1H NMR metabolomics data. Anal Chem 78: 6: 215–224.

44. Lamers Y, Laners Y, Jerik FR, Vogel HJ (2008) Visualization of GC/TOF-MS-based metabolomics data for identification of unknown signals in quantitative proton NMR mixture analysis. Anal Chem 80: 4430–4442.

45. Lamers Y, Laners Y, Jerik FR, Vogel HJ (2008) Application of biofluid 1H nuclear magnetic resonance-based metabolic techniques for the analysis of the biochemical effects of dietary isoalloxazines on human plasma profile. Anal Biochem 323: 197–204.

46. Westerhuis JA, van Velzen EJ, Horvath CT, Smilde AK (2010) Multivariate paired data analysis: multilevelPLS-DA versus OPLS-DA. Metabolomics 6: 119–129.

47. Aristotelis J, Molymp B, Baker MS (2007) Evaluation of endogenous plasma peptide extraction methods for mass spectrometric biomarker discovery. J Proteome Res 6: 571–581.

48. Tredwell GD, Behrends V, Geier FM, Liebke M, Bundy JG (2011) Between-person comparison of metabolite fitting for NMR-based quantitative metabolomics. Anal Chem 63: 8083–8087.

49. Scheer J, Mackley A, Gregory JF (2005) Activities of hepatic cytosolic and mitochondrial forms of serine hydroxymethyltransferase and hepatic glycine concentration are affected by vitamin B6 intake in rats. J Nutr 135: 233–238.

50. Njihou H, Gregory J, Fitzpatrick C, Cio E, Lamers K, et al. (2009) A mathematical model gives insights into the effects of vitamin B-6 deficiency on 1-carbon and glutathione metabolism. J Nutr 139: 794–791.

51. Lamers Y, Williamson J, Theriaque D, Shuster J, Gilbert L, et al. (2009) Production of 1-carbon units from glycine is extensive in healthy men and women. J Nutr 139: 666–671.

52. Carthoes WP, Watford M (1995) Regulation of glutamine activity and glutamine metabolism. Annu Rev Nutr 15: 133–159.

53. Broman JT (2003) Interorgan amino acid transport and its regulation. J Nutr 133: 2068S–2072S.

54. Sauberlich HE, Canham JE, Baker EM, Raica N Jr, Herman YF (1972) Biochemical assessment of the nutritional status of vitamin B 6 in the human. Am J Clin Nutr 23: 629–642.

55. Marlanse SG, Molamy SM, Reinke SN, Sykes BD, Bronman ME, et al. (2012) Formate can differentiate between hyperhomocysteinemia due to impaired remethylation and impaired transulfuration. Am J Physiol Endocrinol Metab 302: E61–67.

56. Midtun O, Utvik A, Ringdell Pedersen E, Ebbing M, Bleie O, et al. (2011) Low plasma vitamin B-6 status affects metabolism through the kynurenine pathway in cardiovascular patients with systemic inflammation. J Nutr 141: 611–617.

57. Vilien RW, Muirer JF, Glazer HS, Jardro T, Abraham J, et al. (1953) The influence of dietary vitamin B6 deficiency induced by desoxyxypyrдинone in human beings. J Lab Clin Med 42: 335–357.

58. Lema CP, Davis SR, Mackey AD, Scher J, Williamson J, et al. (2006) Vitamin B-6 deficiency suppresses the hepatic transulfuration pathway but increases glutathione concentration in rats fed AIN-76A or AIN-76G diets. J Nutr 136: 2141–2147.

59. Lamers Y, O'Rourke B, Gilbert L, Keeling C, Mackley A, et al. (2009) Vitamin B-6 restriction tends to reduce the red blood cell glutathione synthesis rate without affecting red blood cell or plasma glutathione concentrations in healthy men and women. Am J Clin Nutr 90: 336–343.

60. Bendereller M, Hadji Saad F, Funes M, Maupol V, Guillaud JC, et al. (1996) Effects of exhaustive exercise and vitamin B6 deficiency on free radical oxidative process in male trained rats. Free Radic Biol Med 21: 541–549.

61. Taya S (2005) Oxidant/antioxidant status in liver tissue of vitamin B6 deficient rats. Clin Nutr 24: 383–389.

62. Capurro L, Bergami R, Fiorentini D, Marchetti M, Landi L, et al. (1998) Vitamin B6 deficiency affects antioxidant defences in rat liver and heart. Biochem Mol Biol Int 46: 689–697.